GSK invests $270M into vaccine manufacturing in Belgium

GSK is investing about $270 million (€250 million) to build out and expand its vaccine manufacturing facilities in Wavre, Belgium.

The plant is expected to have two wings: one for producing its “non-live” vaccines, including the newly approved RSV vaccine Arexvy and the shingles vaccine Shingrix, and the other wing will make “live” vaccines, including Varilrix for chickenpox and Priorix for measles.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Maternal mRNA COVID-19 vaccination shields infants for six months

Women who receive an mRNA-based COVID-19 vaccination or booster during pregnancy can provide their infants with strong protection against symptomatic COVID-19 infection for at least

February 16, 2024

After its last deal fell through, Maze Therapeutics finds new partner for rare disease drug

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

May 10, 2024

Liquid biopsy may be used to identify gene mutations in pediatric arteriovenous malformations

A study presented today at the Society of NeuroInterventional Surgery’s (SNIS) 20th Annual Meeting indicated that it may be possible to use a less invasive

August 3, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.